Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs

Patients with type 2 diabetes are at increased risk of developing heart failure, cardiovascular death and renal failure. The recent results of three large sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials have demonstrated a reduction in heart failure hospitalisation and progre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas A Zelniker, Eugene Braunwald
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/841865a83ad748579e673a5628ea7f0f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:841865a83ad748579e673a5628ea7f0f
record_format	dspace
spelling	oai:doaj.org-article:841865a83ad748579e673a5628ea7f0f2021-12-04T16:00:49ZTreatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs10.15420/cfr.2018.44.12057-75592057-7540https://doaj.org/article/841865a83ad748579e673a5628ea7f0f2019-01-01T00:00:00Zhttps://www.cfrjournal.com/articles/HF-Inhibitors-diabetichttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Patients with type 2 diabetes are at increased risk of developing heart failure, cardiovascular death and renal failure. The recent results of three large sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials have demonstrated a reduction in heart failure hospitalisation and progressive renal failure. One trial also showed a fall in cardiovascular and total death. A broad spectrum of patients with diabetes benefit from these salutary effects in cardiac and renal function and so these trials have important implications for the management of patients with type 2 diabetes. Selected glucagon-like peptide 1 receptor agonists have also been shown to reduce adverse cardiovascular outcomes.Thomas A ZelnikerEugene BraunwaldRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 5, Iss 1, Pp 27-30 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Thomas A Zelniker Eugene Braunwald Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
description	Patients with type 2 diabetes are at increased risk of developing heart failure, cardiovascular death and renal failure. The recent results of three large sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials have demonstrated a reduction in heart failure hospitalisation and progressive renal failure. One trial also showed a fall in cardiovascular and total death. A broad spectrum of patients with diabetes benefit from these salutary effects in cardiac and renal function and so these trials have important implications for the management of patients with type 2 diabetes. Selected glucagon-like peptide 1 receptor agonists have also been shown to reduce adverse cardiovascular outcomes.
format	article
author	Thomas A Zelniker Eugene Braunwald
author_facet	Thomas A Zelniker Eugene Braunwald
author_sort	Thomas A Zelniker
title	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
title_short	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
title_full	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
title_fullStr	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
title_full_unstemmed	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
title_sort	treatment of heart failure with sodium-glucose cotransporter 2 inhibitors and other anti-diabetic drugs
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/841865a83ad748579e673a5628ea7f0f
work_keys_str_mv	AT thomasazelniker treatmentofheartfailurewithsodiumglucosecotransporter2inhibitorsandotherantidiabeticdrugs AT eugenebraunwald treatmentofheartfailurewithsodiumglucosecotransporter2inhibitorsandotherantidiabeticdrugs
_version_	1718372804860051456

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs

Ejemplares similares